A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?
Open Access
- 10 January 2012
- journal article
- review article
- Published by Springer Nature in Child and Adolescent Psychiatry and Mental Health
- Vol. 6 (1) , 2
Abstract
The safety of paediatric medications is paramount and contraindications provide clear pragmatic advice. Further advice may be accessed through Summaries of Product Characteristics (SPCs) and relevant national guidelines. The SPC can be considered the ultimate independent guideline and is regularly updated. In 2008, the authors undertook a systematic review of the SPC contraindications of medications licensed in the United Kingdom (UK) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). At that time, there were fewer contraindications reported in the SPC for atomoxetine than methylphenidate and the specific contraindications varied considerably amongst methylphenidate formulations. In 2009, the European Medicines Agency (EMA) mandated harmonisation of methylphenidate SPCs. Between September and November 2011, there were three changes to the atomoxetine SPC that resulted in revised prescribing information. In addition, Clinical Guidance has also been produced by the National Institute for Health and Clinical Excellence (NICE) (2008), the Scottish Intercollegiate Guidelines Network (SIGN) (2009) and the British National Formulary for Children (BNFC).Keywords
This publication has 10 references indexed in Scilit:
- A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?Child and Adolescent Psychiatry and Mental Health, 2012
- Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHDCurrent Medical Research and Opinion, 2010
- Effects of Atomoxetine With and Without Behavior Therapy on the School and Home Functioning of Children With Attention-Deficit/Hyperactivity DisorderThe Journal of Clinical Psychiatry, 2010
- Attention-Deficit/Hyperactivity Disorder Diagnosis, Co-Morbidities, Treatment Patterns, and Quality of Life in a Pediatric Population in Central and Eastern Europe and AsiaJournal of Child and Adolescent Psychopharmacology, 2009
- Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adultsThe British Journal of Psychiatry, 2009
- A systematic review of the contra-indications in the summary of product characteristics for drugs licensed for ADHD in the UKEuropean Psychiatry, 2008
- Meta-Analysis of Suicide-Related Behavior Events in Patients Treated With AtomoxetineJournal of the American Academy of Child & Adolescent Psychiatry, 2008
- The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression AnalysisAmerican Journal of Psychiatry, 2007
- The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression AnalysisAmerican Journal of Psychiatry, 2007
- Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for PsychopharmacologyJournal of Psychopharmacology, 2007